Invasive Candidiasis in Adult Patients with COVID-19: Results of a Multicenter Study in St. Petersburg, Russia

Author:

Kozlova Olga1ORCID,Burygina Ekaterina1,Khostelidi Sofya1,Shadrivova Olga1ORCID,Saturnov Andrey2,Gusev Denis3,Rysev Aleksandr4,Zavrazhnov Anatoliy5,Vashukova Maria3ORCID,Pichugina Galina4,Mitichkin Mikhail5,Kovyrshin Sergey1ORCID,Bogomolova Tatiana1,Borzova Yulia1,Oganesyan Ellina1,Vasilyeva Natalya1,Klimko Nikolay1ORCID,

Affiliation:

1. Kashkin Research Institute of Medical Mycology; North-Western State Medical University Named after I.I. Mechnikov, 191015 Saint-Petersburg, Russia

2. Leningrad Regional Hospital, 194291 Saint-Petersburg, Russia

3. Botkin’s Hospital, 195067 Saint-Petersburg, Russia

4. Saint Petersburg Research Institute of Emergency Medicine n.a. I.I. Dzhanelidze, 192242 Saint-Petersburg, Russia

5. City Mariinskaya Hospital, 191014 Saint-Petersburg, Russia

Abstract

We studied the risk factors, etiology, clinical manifestations, and treatment outcomes of COVID-19-associated invasive candidiasis (COVID-IC) in adult patients admitted to six medical facilities in St. Petersburg. (November 2020–December 2022). In this retrospective study, we included 72 patients with COVID-IC with a median age of 61 years (range 29–96), 51% of whom were women. The predisposing factors for COVID-IC were a central venous catheter (CVC) for more than 10 days (the odds ratio (OR) = 70 [15–309]), abdominal surgical treatment performed in the previous 2 weeks (OR = 8.8 [1.9–40.3]), bacteremia (OR = 10.6 [4.8–23.3]), pulmonary ventilation (OR = 12.9 [5.9–28.4]), and hemodialysis (OR = 11.5 [2.5–50.8]). The signs and symptoms of COVID-IC were non-specific: fever (59%), renal failure (33%), liver failure (23%), and cardiovascular failure (10%). Candida albicans (41%) predominated among the pathogens of the candidemia. The multidrug-resistant Candida species C. auris (23%) and C. glabrata (5%) were also identified. Empirical therapy was used in 21% of COVID-IC patients: azole-93%, echinocandin–7%. The majority of COVID-IC patients (79%) received, after laboratory confirmation of the diagnosis of IC, fluconazole (47%), voriconazole (25%), echinocandin (26%), and amphotericin B (2)%. The 30 days overall survival rate was 45%. The prognosis worsened concomitant bacteremia, hemodialysis, and long-term therapy by systemic glucocorticosteroids (SGCs), bronchial colonization with Candida spp. The survival prognosis was improved by the early change/replacement of CVC (within 24 h), the initiation of empirical therapy, and the use of echinocandin. Conclusions: We highlighted the risk factors that predispose COVID-19 patients to candidiasis and worsen the survival prognosis. Their individual effects in patients with COVID-19 must be well understood to prevent the development of opportunistic co-infections that drastically lower chances of survival.

Publisher

MDPI AG

Subject

Plant Science,Ecology, Evolution, Behavior and Systematics,Microbiology (medical)

Reference29 articles.

1. Dysregulation of Immune Response in Patients with Coronavirus 2019 (COVID-19) in Wuhan, China;Qin;Clin. Infect. Dis.,2020

2. Kraevoy, S.A., Kostenko, N.A., Kamkin, E.G., Avdeev, S.N., Adamyan, L.V., Baranov, A.A., Baranova, N.N., Boyko, E.A., Briko, N.I., and Vasilyeva, I.A. (2022, November 21). Prevention, Diagnosis and Treatment of the Coronavirus Infection (COVID-19). Temporary Guidelines. Ministry of Health of the Russian Federation. Volume. Version 3. 3 March 2020. (In Russian).

3. Results of a prospective multicenter study of the use of anidulafungin—ERA (Eraksis in the Russian Federation);Klimko;Probl. Med. Mycol.,2018

4. Incidence of co-infections and superinfections in hospitalised patients with COVID-19: A retrospective cohort study;Sanjuan;Clin. Microbiol. Infect.,2021

5. Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April–July 2020;Chowdhary;Emerg. Infect. Dis.,2020

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3